Literature DB >> 22903675

How immune complexes from certain IgG NAbs and any F(ab')₂ can mediate excessive complement activation.

Hans U Lutz1.   

Abstract

In sepsis death follows an excessive inflammatory response involving cytokines and complement that is activated primarily via the amplifying C3/C5 convertase. Excessive stimulation of complement amplification requires IgG-containing or F(ab')₂-containing immune complexes (IC) that capture dimeric C3b on one of their heavy chains or heavy chain fragments. The ability of IgG-IC to capture dimeric C3b by the Fab portion is dependent on an affinity for C3 within the Fab portion, but outside the antigen-binding region. This property is rare among IgG NAbs. In contrast to this, the lack of the Fc portion renders the Fab regions of any F(ab')(2)-IC accessible to nascent C3b, but dimeric C3b deposits only if F(ab')₂-IC form secondary IC with anti-hinge NAbs that rigidify the complex and thereby promote deposition of dimeric C3b. Both types of complexes, C3b₂-IgG-IC and C3b₂-F(ab')₂-IC/anti-hinge NAbs, are potent precursors of alternative C3 convertases and stimulate complement amplification along with properdin up to 750 times more effectively than C3b and properdin. F(ab')₂ fragments are not normally generated, but are formed from NAbs by enzymes from pathogens and neutrophils in sepsis. Unlike IgG-IC F(ab')₂-IC are not cleared by Fc-receptor dependent processes and circulate long enough to form secondary IC with anti-hinge NAbs that rigidify the complexes such that they capture dimeric C3b and gain the potency to stimulate complement amplification.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22903675      PMCID: PMC7123756          DOI: 10.1007/978-1-4614-3461-0_14

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  43 in total

1.  Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.

Authors:  E Jelezarova; A Vogt; H U Lutz
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

2.  C3b2-IgG complexes retain dimeric C3 fragments at all levels of inactivation.

Authors:  Emiliana Jelezarova; Alexander Luginbuehl; Hans U Lutz
Journal:  J Biol Chem       Date:  2003-10-03       Impact factor: 5.157

3.  The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions.

Authors:  Y M Lucisano Valim; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

4.  A neutrophil elastase inhibitor, sivelestat, ameliorates lung injury after hemorrhagic shock in rats.

Authors:  Yuichiro Toda; Toru Takahashi; Kyoichiro Maeshima; Hiroko Shimizu; Kazuyoshi Inoue; Hiroshi Morimatsu; Emiko Omori; Mamoru Takeuchi; Reiko Akagi; Kiyoshi Morita
Journal:  Int J Mol Med       Date:  2007-02       Impact factor: 4.101

5.  The natural human IgG anti-F(ab')2 antibody recognizes a conformational IgG1 hinge epitope.

Authors:  P Terness; I Kohl; G Hübener; R Battistutta; L Moroder; M Welschof; C Dufter; M Finger; C Hain; M Jung
Journal:  J Immunol       Date:  1995-06-15       Impact factor: 5.422

6.  Neutrophil elastase inhibitor improves survival of rats with clinically relevant sepsis.

Authors:  Koichi Suda; Hiroya Takeuchi; Tomoko Hagiwara; Taku Miyasho; Minoru Okamoto; Kazufumi Kawasako; Shingo Yamada; Kazuhiro Suganuma; Norihito Wada; Yoshiro Saikawa; Koichi Fukunaga; Yosuke Funakoshi; Satoru Hashimoto; Hiroshi Yokota; Ikuro Maruyama; Akitoshi Ishizaka; Yuko Kitagawa
Journal:  Shock       Date:  2010-05       Impact factor: 3.454

7.  Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies.

Authors:  Nirmal K Banda; Allyson K Wood; Kazue Takahashi; Brandt Levitt; Pauline M Rudd; Louise Royle; Jodie L Abrahams; Gregory L Stahl; V Michael Holers; William P Arend
Journal:  Arthritis Rheum       Date:  2008-10

8.  A neutrophil elastase inhibitor, sivelestat, reduces lung injury following endotoxin-induced shock in rats by inhibiting HMGB1.

Authors:  Satoshi Hagiwara; Hideo Iwasaka; Kazumi Togo; Takayuki Noguchi
Journal:  Inflammation       Date:  2008-08       Impact factor: 4.092

9.  Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs.

Authors:  Randall J Brezski; Jennifer L Luongo; Diane Petrone; Mary H Ryan; Degang Zhong; Susan H Tam; Albert P Schmidt; Marian Kruszynski; Brian P Whitaker; David M Knight; Robert E Jordan
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

10.  The role of immunoglobulins in alternative complement pathway activation by zymosan. I. Human IgG with specificity for Zymosan enhances alternative pathway activation by zymosan.

Authors:  H A Schenkein; S Ruddy
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

View more
  3 in total

1.  Glycomic signatures on serum IgGs for prediction of postvaccination response.

Authors:  Jing-Rong Wang; Wen-Da Guan; Lee-Fong Yau; Wei-Na Gao; Yang-Qing Zhan; Liang Liu; Zi-Feng Yang; Zhi-Hong Jiang
Journal:  Sci Rep       Date:  2015-01-23       Impact factor: 4.379

2.  Pain-associated biomarkers in breast cancer.

Authors:  C Diaconu; C Pantis; C Cirimbei; C Bordea; M I Gruia; A Blidaru
Journal:  J Med Life       Date:  2015 Jan-Mar

3.  Convalescent serum therapy for COVID-19: A 19th century remedy for a 21st century disease.

Authors:  Daniel Montelongo-Jauregui; Taissa Vila; Ahmed S Sultan; Mary Ann Jabra-Rizk
Journal:  PLoS Pathog       Date:  2020-08-12       Impact factor: 6.823

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.